Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)

• Published in: Frontiers in oncology Vol. 9; p. 475
• Main Authors: Bian, Benjamin, Juiz, Natalia Anahi, Gayet, Odile, Bigonnet, Martin, Brandone, Nicolas, Roques, Julie, Cros, Jérôme, Wang, Nenghui, Dusetti, Nelson, Iovanna, Juan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media 05-06-2019; Frontiers Media S.A
• Subjects: c-MYC; Cancer; Human health and pathology; Hépatology and Gastroenterology; JQ1; Life Sciences; NHWD-870; Oncology; organoids; pancreatic cancer; pancreatic cancer; JQ1; c-MYC; organoids; NHWD-870
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2019.00475

Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease, therefore stratification of patients is essential to predict their responses to therapies and to choose the best treatment. PDAC-derived organoids were produced from PDTX and Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA) biopsies. A signature based on 16 genes targets of the c-MYC oncogene was applied to classify samples into two sub-groups with distinctive phenotypes named MYC-high and MYC-low. The analysis of 9 PDTXs and the corresponding derived organoids revealed that this signature which was previously designed from PDTX is transferable to the organoid model. Primary organoids from 24 PDAC patients were treated with NHWD-870 or JQ1, two inhibitors of c-MYC transcription. Notably, the comparison of their effect between the two sub-groups showed that both compounds are more efficient in MYC-high than in MYC-low samples, being NHWD-870 the more potent treatment. In conclusion, this study shows that the molecular signatures could be applied to organoids obtained directly from PDAC patients to predict the treatment response and could help to take the more appropriate therapeutic decision for each patient in a clinical timeframe.